The LOGIC-2 trial (NCT02159066) evaluated the efficacy of adding one of four other agents including ribociclib (CDK4/6i) to encorafenib (BRAFi) and binimetinib (MEKi) in 38 patients with advanced BRAF V600-mutated melanoma who progressed on encorafenib and binimetinib. The gene discussed is BRAF; the disease is melanoma.